Why MGRC

Leading the Future of Personalised Healthcare

At Malaysian Genomics Resource Centre (MGRC), we pioneer advanced biotechnologies to transform healthcare outcomes. As one of Malaysia’s top listed biotech companies, our expertise spans across genomics, stem cell therapy, immunotherapy, and precision medicine.

Founded in

2004

2010

Listed on the ACE Market
of Bursa Malaysia

What Sets Us Apart

Proven Track Record

Founded in 2004 and listed on the ACE Market of Bursa Malaysia since 2010, we bring nearly two decades of innovation and leadership in biotechnology.

Integrated Solutions

From genomic diagnostics to stem cell therapies and immunotherapies, we provide end-to-end personalised healthcare solutions powered by clinical science.

Global-Standard Facilities

Equipped with high-throughput sequencing labs, cGMP-certified production lines, and ISO-accredited testing capabilities.

Trusted by Professionals

We work with hospitals, clinicians, and research centres across Southeast Asia to deliver medically validated, patient-centric solutions.

Commitment to Quality

Our processes meet stringent international standards, with a focus on safety, efficacy, and traceability at every stage.

Empowering Health, Enhancing Lives

Our mission is to improve quality of life through science-backed, accessible, and future-forward health innovations.

Vision

To be Asia’s leading innovator in genomics, regenerative medicine, and immunotherapy—improving lives through the science of tomorrow.

Mission

To deliver world-class, personalised healthcare solutions through cutting-edge biotechnology, anchored in safety, integrity, and scientific excellence.

Our Milestones

Year Milestone

2004

Incorporation of Malaysian Genomics Resource Centre Berhad (MGRC)

Established as a pioneer in genome sequencing and bioinformatics.

2010

Listed on ACE Market of Bursa Malaysia

Became one of the first biotechnology companies to go public in Malaysia.

2012

Proprietary Dtect® Genetic Screening Tests

Introduced the first suite of preventive genetic tests tailored for Asian populations.

2015

Expanded into Stem Cell Therapies

Introduced Mesenchymal Stem Cell (MSC) and Exosome-based regenerative programs.

2021

Introduced Immunotherapy Services

Launched NK Cell and CAR-T cell programs to support cancer and immune-related treatment options.

2023

Launched Compounding Pharmacy & NAD+ IV Programs

Supporting holistic wellness through precision compounding and anti-aging infusion therapies.

2025

Expanded Internationally with Clinical Collaborations

Strengthened regional footprint through hospital and specialist clinic partnerships across Southeast Asia.